TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In good general health~* Susceptible to human rhinovirus type 16 (HRV-16)~* Male or non-pregnant and non-breast feeding female~* If female of reproductive potential, agrees to use 1 form of acceptable birth control~Exclusion Criteria:~* Donated blood within 56 days or donated plasma within 7 days prior to dosing~* History of significant multiple and/or severe allergies~* Recent history of respiratory tract infection~* History of cancer~* Body mass index \<18 kg/m\^2 or ≥40 kg/m\^2~* History of major surgery or loss of 1 unit of blood~* History of allergic reaction to sulfonamides~* Received medications within 14 days prior to randomization~* Significantly abnormal laboratory tests at Screening~* Current smoker, smoked within 5 years of Screening, or significant past smoking history~* History of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Gefapixant 45 mg BID (Type: EXPERIMENTAL): Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
- Placebo BID (Type: PLACEBO_COMPARATOR): Participants will receive a matching placebo tablet BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (ages 18 years or older)~* Best corrected visual acuity \< 20/40 but no worse than 20/800 in the study eye~* Best corrected visual acuity better than or equal to 20/200 in the fellow eye~* Post-surgical CME in the study eye as documented on OCT (central subfield \>/= 250 microns)~* Women of child-bearing potential who are interested in participating in this study will use two effective forms of contraception prior to initiation of pegaptanib and then throughout the remainder of the study. For women of childbearing potential, results from a urine pregnancy test will be obtained prior to each injection with pegaptanib. Urine samples will be disposed of after the test is performed.~* Initiation of pegaptanib or sham injections may begin following at least 12 weeks of topical therapy for CME after cataract surgery or the other eye,if the best-corrected visual acuity has not improved by at least 5 letters and if the center point thickening on OCT has not improved by at least 20%. Patients who have been on topical ketorolac for greater than 12 weeks are still eligible for this study.~Exclusion Criteria:~* History of intravitreal steroid (triamcinolone) injection into the study eye or fellow eye within 4 months prior to cataract surgery~* CME due to other etiologies such as vein occlusion and diabetes.~* Retinal diseases that preclude evaluation of the macula for edema (e.g., macular hole).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Critically ill adult patient (≥ 18 years) admitted to ICU~* Has acute respiratory failure (ARF) i.e. expected to remain mechanically ventilated for more than 48 hours~* Expected ICU dependency of 5 or more days~* On or expected to initiate enteral nutrition within 7 days of ICU admission~* BMI \<25 or ≥ 35 based on pre-ICU actual or estimated dry weight~Exclusion Criteria:~* \>72 hours from admission to ICU to time of consent~* Not expected to survive an additional 48 hrs from screening evaluation~* A lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated DNR acceptable)~* Patients already receiving PN at screening~* Absence of All gastrointestinal risk factors, defined as:~  1. High Apache II Score (\>20)~ 2. On more than 1 vasopressor or increasing doses or vasopressors~ 3. Receiving continuous infusion of narcotics~ 4. High nasogastric/orogastric output (\>500 mL over 24 hours)~ 5. Recent surgery involving esophagus, stomach, or small bowel OR peritoneal contamination with bowel contents~ 6. Pancreatitis~ 7. Multiple gastrointestinal investigations~ 8. Recent history of diarrhea/C. Difficile~ 9. Surgical patients with future surgeries planned~ 10. Ruptured or dissected abdominal aortic aneurysm~* Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma~* Pregnant or lactating patients~* Patients with clinical fulminant hepatic failure~* Patients with Cirrhosis Child's Class C Liver Disease (except those on a transplant list or transplantable)~* Dedicated port of central line not available~* Known allergy to study nutrients (soy, eggs or olive products)~* Enrolment in another industry sponsored ICU intervention study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enteral Nutrition + Parenteral Nutrition (Type: EXPERIMENTAL): Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
- Enteral Nutrition Only (Type: NO_INTERVENTION): Enteral nutrition only - no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sutureless vs Sutured Gastroschisis Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Inclusion criteria are the diagnosis of gastroschisis, birth weight of 1500 grams or greater, and gestational age of 34 weeks or more.~Exclusion Criteria:Exclusion criteria are infants with other major abnormalities or medical conditions, grade IV intraventricular hemorrhage, inability to obtain informed consent, and the presence of a closed-type gastroschisis defect.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sutured closure (Type: ACTIVE_COMPARATOR): None
- Sutureless closure (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary or recurrent biliary duct carcinoma from the proximal, middle, or distal bile ducts~* Measurable or evaluable disease that is considered resectable~* No distant metastases~  * No non-contiguous liver metastases~ * Resectable extension into adjacent liver allowed~ * No metastasis to peritoneal cavity~ * No Bismuth type 4 lesion or metastasis to celiac axis or para-aortic lymph nodes~* No tumor encasement of portal vein or hepatic artery~* No gross ascites~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* No cirrhosis~* No active cholangitis~* No fever or signs of infection in biliary drainage system~* Measurement of C-reactive protein optimal~* Bilirubin less than 3 mg/dL~Renal:~* Creatinine less than 1.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Other:~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception during and for 3 months after study~* No weight loss greater than 20% ideal body weight~* No active duodenal or gastric ulcers~* No other prior or concurrent primary malignancy except adequately treated carcinoma in situ of the cervix or basal cell carcinoma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer confirmed by histology or cytology~* At least one measurable lesion~* Advanced disease refractory to standard therapy or for which no standard therapy exists~* Life expectancy at least 3 months~Exclusion Criteria:~* Known secondary neoplasia or central nervous system (CNS) metastases, acute or chronic leukemia, lymphoma or multiple myeloma~* Body weight below 45 kg~* Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective birth control methods~* Concurrent severe or uncontrolled medical disease~* Acute or chronic liver disease~* Confirmed diagnosis of HIV~* Insulin dependent diabetes mellitus/abnormal glucose tolerance test (GTT)/latent diabetes mellitus type I or II~* Chemotherapy or radiotherapy less than 4 weeks prior to entry~* Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)~* Participation in a clinical trial less than 30 days prior to entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AMT2003 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: BLeeding Events and Maintenance DoSe of PraSugrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all ACS patients treated with PCI (percutaneous coronary intervention) and dual antiplatelet therapy (DAPT: aspirin plus prasugrel).~* Informed written consent~Exclusion Criteria:~* Age \< 18 years~* Active bleeding; bleeding diathesis; coagulopathy~* History of gastrointestinal or genitourinary bleeding \<2 months~* Major surgery in the last 6 weeks~* History of intracranial bleeding or structural abnormalities~* Suspected aortic dissection~* Any previous TIA (transient ischemic attack)/stroke~* Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .~* Known relevant hematological deviations: Hb \<10 g/dl, Thrombocytopenia. \<100x10\^9/l~* Use of coumadin derivatives within the last 7 days~* Chronic therapy with prasugrel or ticagrelor~* Known malignancies or other comorbid conditions with life expectancy \<1 year~* Known severe liver disease, severe renal failure~* Known allergy to the study medications~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel dose 5 mg/day (Type: EXPERIMENTAL): 225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
- Prasugrel dose 10 mg/day (Type: ACTIVE_COMPARATOR): 225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test if TEV-48574 is Effective in Relieving Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant has a diagnosis of asthma for at least 12 months prior to the initial screening visit.~* The participant is able to perform technically acceptable and repeatable spirometry, including with a hand-held spirometer, after training~* The participant has had at least one documented clinical asthma exacerbation in the 18 months prior to (but not within 30 days of) the initial screening visit.~* The participant is a non-smoker for ≥6 months with lifetime history ≤10 pack-years, with no current ecigarette or marijuana use.~NOTE- Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* The participant has any concomitant conditions or treatments that could interfere with study conduct.~* The participant is currently pregnant or lactating or is planning to become pregnant during the study.~* The participant has received any live or attenuated vaccine within 15 days of the initial screening visit.~NOTE- Additional criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TEV-48574 (Type: EXPERIMENTAL): Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rare Tumor Case Review

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children with intrapericardial teratoma tumors

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Intervention in Malnourished Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index \< 20 kg/m2~* Medical In/Outpatient or District Nurse-patient~* Able to take nutritional supplement (sip feeding)~* Able to walk~* Written patient informed consent~Exclusion Criteria:~* Actual malignancy~* Dementia with a Mini Mental Status score \< 24~* Severe depression~* Need for Total Parenteral Nutrition or Tube Feeding~* Prescribed nutritional supplements during more than the last week~* Life expectancy of less than 6 months

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutritional supplement (Type: EXPERIMENTAL): 2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
- Dietary advice (Type: ACTIVE_COMPARATOR): ordinary dietary advice with a recommendation of four meals per day or similar dietary advice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants will be frontline hospital or long-term care home staff involved in the management of COVID-19 patients in Canada or The United States of America.~2. Participants will be aged 18 to 70.~3. Participants will be willing and able to attend, via WebEx software, the introductory phase of SKY or HEP, as well as at least two of the four weekly follow-up sessions~4. Have sufficient hearing to follow verbal instructions.~5. Have an adequate understanding of English.~6. Able to sit without physical discomfort for 60 minutes.~7. Not pregnant and willing to remain not pregnant for the duration of the study.~Exclusion Criteria:~1. Inability to independently provide informed consent.~2. Current suicidality as assessed by the suicide item of the Patient Health Questionnaire-9 scale.~3. History of bipolar disorder.~4. History of chronic PTSD.~5. History of schizophrenia or schizoaffective disorder.~6. Currently practice any type of formal meditation, mindfulness, or breathing techniques regularly (greater than 3 times per week).~7. History of complex PTSD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Sudarshan Kroya Yoga (SKY) (Type: EXPERIMENTAL): Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered.
- Health Enhancement Program (HEP) (Type: ACTIVE_COMPARATOR): The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The online version of HEP for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered. HEP will be taught by Dr. Paris Lai, co-investigator and senior psychiatry resident.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older.~* Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.~* Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study.~* Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in a EXPAREL study within the last 30 days.~* Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~* Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery.~In addition, the patient will be ineligible if he/she meets the following criteria during surgery:~* Patients with unplanned multiple segmental resections or large intestine.~* Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV morphine sulfate (Type: ACTIVE_COMPARATOR): morphine sulfate (or Sponsor-approved equivalent)
- EXPAREL (Type: EXPERIMENTAL): EXPAREL (bupivacaine liposome injectable suspension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues